Ocugen shares hold at $1.06 after negative gene therapy trial data
AI Summary- Ocugen shares stayed flat after interim data showed a negative treatment effect in its gene therapy trial.
- $1.06 was Ocugen’s share price Thursday, near its 52-week low of $1.01.
- Ocugen’s monitoring committee recommended continuing the study for eight months.